Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience

Endocrine

Volumn 55, Issue 1, 2017, Pages 173-178

  Deol, Herpreet ^a   Lekkakou, Leoni ^a   Viswanath, Ananth K ^a   Pappachan, Joseph M ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

Author keywords

Anti diabetic combination regimen; Diabesity; Glucagon like peptide 1 (GLP 1) agonist; Management of diabesity; Sodium glucose co transporter type 2 (SGLT 2) inhibitors

Indexed keywords

CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MALE; MEDICAL CARE; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; WEIGHT REDUCTION; WORK EXPERIENCE; AGONISTS; COMBINATION DRUG THERAPY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84989180878     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-016-1125-0     Document Type: Article

References (25)

1. World Health Organization. Obesity and overweight. Geneva, Switzerland: World Health Organization, 2015. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed 30 March 2016
2. E.A. Sims, E. Danforth Jr, E.S. Horton, G.A. Bray, J.A. Glennon, L.B. Salans, Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29, 457–496 (1973)
3. P.R. Schauer, D.L. Bhatt, J.P. Kirwan, K. Wolski, S.A. Brethauer, S.D. Navaneethan, A. Aminian, C.E. Pothier, E.S. Kim, S.E. Nissen, S.R. Kashyap, STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N. Engl. J. Med. 370, 2002–2013 (2014)
4. G. Mingrone, S. Panunzi, A. De Gaetano, C. Guidone, A. Iaconelli, G. Nanni et al., Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386(9997), 964–973 (2015)
5. G.F. Paulus, L.E. de Vaan, F.J. Verdam, N.D. Bouvy, T.A. Ambergen, L.W. van Heurn, Bariatric surgery in morbidly obese adolescents: a systematic review and meta-analysis. Obes. Surg. 25, 860–878 (2015)
6. R.M. Saroka, M.P. Kane, R.S. Busch, J. Watsky, R.A. Hamilton, SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM. Endocr. Pract. 21, 1315–1322 (2015)
7. K. Kaku, H. Maegawa, Y. Tanizawa, A. Kiyosue, Y. Ide, T. Tokudome, Y. Hoshino, J. Yang, A.M. Langkilde, Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther 5, 415–433 (2014)
8. L. Curtis, M.A. Humayun, J. Walker, K. Hampton, H. Partridge, Addition of SGLT2 inhibitor to GLP-1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control. Practical Diabetes 33, 129–132 (2016)
9. K. Esposito, P. Chiodini, A. Capuano, M.I. Maiorino, G. Bellastella, D. Giugliano, Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 46, 43–51 (2014)
10. R.R. Henry, J.B. Buse, G. Sesti, M.J. Davies, K.H. Jensen, J. Brett, R.E. Pratley, Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobinA(1c): a meta-analysis of the liraglutide development program. Endocr. Pract. 17, 906–913 (2011)
11. J. Rosenstock, L. Hansen, P. Zee, Y. Li, W. Cook, B. Hirshberg, N. Iqbal, Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38, 376–383 (2015)
12. R. Huxley, W.P. James, F. Barzi, J.V. Patel, S.A. Lear, P. Suriyawongpaisal, E. Janus, I. Caterson, P. Zimmet, D. Prabhakaran, S. Reddy, M. Woodward, Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes. Rev. 9(Suppl 1), 53–61 (2008)
13. S. Haldar, S.C. Chia, C.J. Henry, Body composition in Asians and Caucasians: comparative analyses and influences on cardiometabolic outcomes. Adv. Food Nutr. Res. 75, 97–154 (2015)
14. D.S. Shyangdan, O.A. Uthman, N. Waugh, SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 6, e009417 (2016)
15. N.M. Maruthur, E. Tseng, S. Hutfless, L.M. Wilson, C. Suarez-Cuervo, Z. Berger, Y. Chu, E. Iyoha, J.B. Segal, S. Bolen, Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann. Intern. Med. 164, 740–751 (2016)
16. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)
17. C. Wanner, S.E. Inzucchi, J.M. Lachin, D. Fitchett, M. von Eynatten, M. Mattheus et al., Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016)
18. S.P. Marso, G.H. Daniels, K. Brown-Frandsen, P. Kristensen, J.F. Mann, M.A. Nauck et al., Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016)
19. M. May, C. Schindler, Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther. Adv. Endocrinol. Metab. 7, 69–83 (2016)
20. S.I. Taylor, J.E. Blau, K.I. Rother, SGLT2 inhibitors may predispose to ketoacidosis. J. Clin. Endocrinol. Metab. 100, 2849–2852 (2015)
21. M.M. Smits, L. Tonneijck, M.H. Muskiet, M.H. Kramer, D.L. Cahen, D.H. van Raalte, Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes Obes. Metab. 18, 224–235 (2016)
22. F. Sun, S. Wu, S. Guo, K. Yu, Z. Yang, L. Li, Y. Zhang, L. Ji, S. Zhan, Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine 48, 794–803 (2015)
23. R.P.Monica Reddy, S.E. Inzucchi, SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53, 364–372 (2016)
24. Y.G. Kim, S. Hahn, T.J. Oh, K.S. Park, Y.M. Cho, Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes. Metab. 16, 900–909 (2014)
25. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck et al., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38, 140–149 (2015)